Integrated Informatics Analysis of Cancer-Related Variants

Kymberleigh A. Pagel, PhD¹; Rick Kim, MS, PhD²; Kyle Moad, BS³; Ben Busby, PhD³; Lily Zheng, BS¹,⁴; Collin Tokheim, PhD⁵; Michael Ryan, MS, PhD²; and Rachel Karchin, MS, PhD¹,⁶

abstract

PURPOSE The modern researcher is confronted with hundreds of published methods to interpret genetic variants. There are databases of genes and variants, phenotype-genotype relationships, algorithms that score and rank genes, and in silico variant effect prediction tools. Because variant prioritization is a multifactorial problem, a welcome development in the field has been the emergence of decision support frameworks, which make it easier to integrate multiple resources in an interactive environment. Current decision support frameworks are typically limited by closed proprietary architectures, access to a restricted set of tools, lack of customizability, Web dependencies that expose protected data, or limited scalability.

METHODS We present the Open Custom Ranked Analysis of Variants Toolkit¹ (OpenCRAVAT) a new open-source, scalable decision support system for variant and gene prioritization. We have designed the resource catalog to be open and modular to maximize community and developer involvement, and as a result, the catalog is being actively developed and growing every month. Resources made available via the store are well suited for analysis of cancer, as well as Mendelian and complex diseases.

RESULTS OpenCRAVAT offers both command-line utility and dynamic graphical user interface, allowing users to install with a single command, easily download tools from an extensive resource catalog, create customized pipelines, and explore results in a richly detailed viewing environment. We present several case studies to illustrate the design of custom workflows to prioritize genes and variants.

CONCLUSION OpenCRAVAT is distinguished from similar tools by its capabilities to access and integrate an unprecedented amount of diverse data resources and computational prediction methods, which span germline, somatic, common, rare, coding, and noncoding variants.

INTRODUCTION

Next-generation sequencing technologies have greatly reduced the cost of genome sequencing, increasing the availability of genomic data and the need for methods to evaluate genomic variants. The majority of variants have unclassified phenotypic consequences, and their systematic exploration is complicated by data resources that are not easily obtainable or combinable. There is a need for more effective, user-friendly genome analysis tools that include interdisciplinary annotations and resources to suit the needs of both novices and bioinformatics experts. Rapid identification of somatic variants relevant to the progression and treatment of cancer are of particular importance to facilitate timely precision patient care. Maintaining patient privacy and data security places additional constraints on variant annotation and analysis, and requires systems that do not expose protected data.

Highly informative variant and gene characteristics are distributed across thousands of published works, spanning resources from the medical, biologic, and bioinformatics domains, including experimental assays, computational variant effect prediction, evolutionary context, population databases, and established pharmacologic relevance. This abundance of variant and gene annotations challenges researchers to broadly discover and deploy the best resources, as well as incorporate them within custom annotation pipelines. Furthermore, prediction algorithm software often requires nontrivial computational expertise to install, configure, and run. Recently, genome-wide pre-computation of predictor outputs for every possible input variant has been undertaken to make computational tools more accessible. Databases that host precomputes, such as dbNSFP (database for non-synonymous single-nucleotide polymorphisms’ functional predictions),²,³ have been instrumental in
exposing users to new tools. However, the datasets available from these resources were designed for machine rather than human access and require substantial programming investment before a user can incorporate them into an annotation pipeline.

Decision support framework (DSF) software tools have been created to integrate multiple annotation resources.4 Well-designed DSFs require substantial software development; therefore, the majority of DSFs are not freely available. The remaining minority of DSFs are either Web-based portals that expose private data or downloadable tools with complicated installation and configuration requirements.5-7

One such Web-based DSF is the Cancer-Related Analysis of Variants Toolkit (CRAVAT), which prioritizes somatic mutations.9 In this work, we present OpenCRAVAT, an extension of CRAVAT with improved data security, a much larger collection of annotations, and the capability to generate dynamic and customizable pipelines.

OpenCRAVAT is a freely available open-source framework for the annotation and visualization of human genetic variation and genomic elements. The framework can rapidly generate publication-quality visualizations of gene networks, provide the distribution of variants per protein, and support BAM file visualization with an embedded version of the Integrative Genomics Viewer (IGV).10 Designed to comprehensively annotate both well-characterized and novel somatic and germline variation, the framework can be flexibly adapted to suit a wide spectrum of human variation research projects. In this article, we describe the underlying architecture and present several case studies.

**METHODS**

**Framework Architecture**

OpenCRAVAT is written in Python, and all code is stored on a public repository. It is open source and free of charge to users, with both command-line and graphical user interface (GUI) functionality. OpenCRAVAT can be installed via user-friendly wizard or through pip. The framework is built around 2 main components: a base module and a store where users can download additional modules. Modules include input format converters, gene mappers, annotators, output format reporters, and graphical widgets. The base module includes converters that support Variant Call Format (VCF), tab-delimited (TSV), and comma-delimited (CSV) text files; a mapper that projects genome positions to transcript, protein sequence and protein structure coordinates; a set of basic widgets and reporters that generate output results files in sqlite3, Excel, TSV, CSV, and VCF formats. OpenCRAVAT supports GRCh38, GRCh37, and GRCh36 human genome reference assemblies, and variants are mapped to all GENCODE isoforms.11 The store offers a large selection of modules, including additional installable converters (Ancestry, 23andMe, dbSNP identifiers); annotators for somatic, de novo, and germline variation (coding and noncoding); and associated widgets and reporters (VCF, pipeline-friendly TSV and CSV).

The store is available through both GUI and command-line interface. Within the GUI, available modules are displayed in a format similar to an app store, where each tool is represented by a tile containing documentation, update status, and one-click installation. After installation, OpenCRAVAT downloads each resource locally, which enables secure analysis of private data. The open store is built for continuous community-driven development, so that newly developed tools and resources can be uploaded and made available to a wide audience. Addition of new resources to the store requires data descriptions, appropriately formatted annotation data, and a small script to allow incorporation of the data by OpenCRAVAT. Module developers can select
whether to openly publish their data or restrict access, with the option to share the module directly with collaborators.

**Using OpenCRAVAT**

Configurable workflows within OpenCRAVAT can be created and executed in either the command line or GUI. OpenCRAVAT generates annotations for input files of human genetic variants. VCF, annotated VCF, basic tabular file format, dbSNP identifiers, 23andMe, and Ancestry.com files are supported. To accommodate family and cohort studies, multiple VCF files can be selected and merged within a single annotation run, in addition to support for multisample VCF files. For each annotation run, the user has the option to include all installed annotators or a subset, allowing for the creation of custom annotation pipelines (Fig 1). On completion of a run, the interactive results viewer can be used for exploratory data analysis and filtering.

Accessible via both command line and GUI, the viewer comprises 4 tabs: Summary, Variant, Gene, and Filter (Fig 2). The Summary tab displays graphical representation of the submitted variant characteristics, as well as submission details, including the selected annotations and data source versions. The Variant and Gene tabs are divided into an interactive table and widget pane. The interactive table displays each variant or gene on a particular row along with the corresponding user-selected annotations. The widget pane includes several interactive elements which graphically display additional information and visualizations of the annotators, including the IGV with BAM file support and a Protein Diagram to visualize protein-level variation. Within the viewer, table columns and widgets can be resized or hidden, and layout preferences can be saved, shared, and applied to other annotation runs. The Filter tab allows users to generate and save filters, which identify variants in selected samples or genes, population allele frequency ranges, genomic locations, by sequence ontology, or custom annotator-specific thresholds. For example, after installation of the gnomAD module, users may choose to annotate their sample with gnomAD allele frequency and then use the Filter tab to reduce their analysis to variants with allele frequency < 0.01. For more complex filtering tasks, the Query Builder allows users to build advanced SQL queries on the Filter tab of the interactive result viewer.

OpenCRAVAT can be installed locally on a user’s computer or on a server, allowing multiple users to submit annotation runs on the same system, with administrator monitoring and maintenance. The server implementation adds user authentication, user-specific storage, user access to history, and shared access to analysis and visualization results. Server installation can be performed on both a shared local system or in a cloud environment, where results storage can be controlled and protected data are secure. The entire catalog of resources can be stored in one place and shared among many users, in addition to analysis results.

**RESULTS**

In the following case studies, we illustrate the capacity of OpenCRAVAT to evaluate phenotypically relevant genetic variations within inputs of differing size and composition.

**Case Study 1: Variant Prioritization in Multiple Lesion Cancer Samples**

Among the somatic variants present in a tumor, a small number of mutations are believed to “drive” tumor growth and may be useful for diagnosis, prognosis, patient stratification, clinical trial eligibility, and selection of appropriate therapies. Of particular interest are clonal driver mutations that occurred in the initiating tumor cell and are present in all tumor cells. Identification of these originating mutations can be enhanced by evaluating mutations from multiple tumor biopsies, including precursor lesions, primary cancers, and metastases from a single patient.

In this case study, we investigated early candidate driver mutations in a patient with high-grade serous ovarian cancer (CGOV62), using VCF and BAM files from a published genomic study of high-grade serous ovarian cancers, including fallopian tube precursor lesions; fallopian tube and ovarian tumors; and omental, rectal, and appendiceal metastases; with a normal fallopian tube epithelium control sample. BAM files from whole-exome sequencing were
downloaded from the European Bioinformatics Institute (EGAS00001002589), and VCF files were generated with MuTect v.1.1.7 using default parameters. The analysis was carried out using the Query Builder (Fig 3A) by:

1. Installing cancer-related annotation modules (Cancer Gene Census and Cancer Gene Landscapes), computational predictors (CHASMplus OV and MutPred), and a visualization module (IGV).
2. Within the interactive interface, selecting the genome version used in the study (hg18), uploading VCF files for each biopsied lesion, selecting the annotators listed in the step 1, and clicking the Annotate button.
3. On the Filter tab, filtering by sample to exclude any germline variants that were present in the normal fallopian tube epithelium sample.
4. To focus on loss-of-function mutations in tumor suppressor genes (TSG) and missense mutations in oncopgenes (OG), applying a Sequence Ontology filter to select either (missense, splice site, frameshift and nonframeshift indels, and stop gain) for TSG or (missense and nonframeshift indels) for OG.
5. Retaining mutations within known OG and TSG as provided by either the Cancer Gene Landscapes or Cancer Gene Census.

Nine mutations were retained after applying these filters, of which 2 were likely clonal mutations: RANBP2:p.M933I and TP53:p.T126N. These mutations were observed in seven of the eight lesions. In the original study, the TP53 mutation was found in an eighth lesion by deep targeted sequencing. The TP53 mutation is a known driver, with CHASMplus OV P value < .01 and is predicted by MutPred to result in loss of sheet structure (P = .0457). The NDEx widget was used to explore interaction partners of the mutated proteins, and the NDEx enrichment tool identified 13 TP53-associated networks from the National Cancer Institute Pathway Interaction Database (Fig 3B). For each truncal mutation, the normal and tumor BAM files were loaded into IGV for viewing and manual validation (Fig 3C). Manual inspection verified that the mutation was truly somatic, it was not present in normal tissue (data not shown), and there was no apparent strand bias.

Case Study 2: Identifying Driver Missense Mutations Among Metastases

We analyzed exome and genome sequencing data for 76 untreated metastases from 20 patients with breast, colorectal, endometrial, gastric, lung, melanoma, pancreatic, and prostate cancers from a recent study on the heterogeneity of functional driver mutations in cancer metastases. This analysis was performed by:

1. Installing the CHASMplus annotator to score mutations as likely cancer drivers and tsvreporter to generate simple tab-delimited output.
2. Assembling a tab-delimited file of 15,765 somatic mutations identified in the study by Reiter et al.
3. Using the command-line interface to generate a CHASMplus score for each mutation: cravat reiter_et_al_2018.txt -n Reiter_2018 -t tsv -l hg19--cleanup -d output.
4. Running a python script `fdr.py` that took in the output file and created a qvalue for each mutation, which is a correction of the CHASMplus P value for multiple hypothesis testing using the false discovery rate of 0.05.

In total, 56 mutations were predicted as drivers, with a significant qvalue (q < 0.01). These included well-known oncogenic alleles (KRAS:p.G12D, SMAD4:p.D351G, and PTEN:p.R173H). There are 6 KRAS mutations present in these samples, including two mutations that have been observed in more than a single sample (KRAS:p.G12D and KRAS:p.G12V; Fig 4A). The NDEX widget shows that the KRAS and PTEN variants both affect the “Class I PI3K signaling events” network (Fig 4B). All data and code needed to reproduce the analysis are available at the OpenCRAVAT website.

Case Study 3: Clinically Actionable Germline Variants in an Individual Genome

We identified germline variants that are suspected to be relevant to cancer in a phenotypically normal individual obtained from the Personal Genome Project (Profile hu3BDC4B). For this analysis, we used databases of single-nucleotide variations (SNVs), indels, and genes with relevance to cancer, including hereditary predisposition: ClinVar, PharmGKB, and the ClinGen Gene annotator, which includes gene-disease associations curated by the ClinGen consortium. The findings for each annotator are as follows:

1. The ClinVar annotator identified dozens of variants relevant to cancer. Variants with the highest potential for clinical relevance include a variant that is protective for lung cancer, two risk-factor variants (lung cancer and cutaneous malignant melanoma), 5 pathogenic non-coding SNVs (acute myeloid leukemia [AML] with maturation), a pathogenic intronic SNV in EHBP1 associated with hereditary prostate cancer, and 16 drug-response variants that affect the dosage, efficacy, toxicity/adverse drug reaction or response to various cancer drugs.

2. The ClinGen Gene annotator identified variants within 43 genes related to cancer phenotypes. Of these, the most impactful variant was a frameshift deletion in PALB2, which ClinGen has identified to be related to “familial ovarian cancer; hereditary nonpolyposis colon cancer; hereditary breast carcinoma; Fanconi anemia complementation group.” An additional 25 genes related to breast, ovarian, colon, and colorectal cancers are affected by missense variants.

3. The PharmGKB annotator identified two variants. First, an intronic variant in GLDC was associated with increased response to citalopram and escitalopram in people with major depressive disorder. GLDC had been annotated by the ClinGen Gene module as associated...
with glycine encephalopathy. Second, a 3 prime UTR variant of ENOSF1 was associated with response to methotrexate. The majority of variants in this patient have no known clinical relevance. Among the variants highlighted by the ClinVar module, only a single variant, related to hereditary prostate cancer, may be suitable to consider informing the patient to encourage early intervention. The ClinGen Gene module does not appear to be of clinical utility for this patient, with the potential exception of the frameshift deletion affecting PALB2, which has been associated with susceptibility to several cancer types. If the individual receives pharmacologic treatment of cancer in their lifetime, the variant-drug annotations from PharmGKB and ClinVar may have clinical utility.

Case Study 4: Occurrence of Somatic Mutations Within Molecular Subgroups Among 182 Patients With AML

For genetically heterogenous cancer types such as AML, partitioning patients into clinical subgroups based on their genomic alterations carries significant prognostic implications. Individuals with AML have previously been partitioned into 11 genomic subgroups, based on patterns of comutation.\(^27,28\) In this case study, we assessed the prevalence of these clinical subgroups using somatic mutations from 182 patients with AML, sequenced by The Cancer Genome Atlas and obtained from the Genomic Data Commons (gdac.cancer.gov). Genomic subgroups that were defined by inversions, translocations, and gene fusion events were omitted from this analysis because these variant types are not currently supported by OpenCRAVAT:

1. **Genomic subgroup 1**: AML with NPM1 mutation. We identified 22 patients in this subgroup, with a total of 11 NPM1 mutations, of which 2 were observed in more than one sample (NPM1:p.W288Cfs*12 and NPM1:p.V156E).

2. **Genomic subgroup 2**: AML with mutated chromatin, RNA-splicing genes, or both. For the second subgroup, we identified 13 patients. The selection of genes under consideration were derived from the list of genes that are required to harbor at least one driver mutation for classification in this subgroup: RUNX1, ASXL1, BCOR, STAG2, EZH2, SRSF2, SF3B1, U2AF1, ZRSR2, or MLLPTD. A total of 17 protein-coding mutations affect these genes, of which three were observed in more than one sample (STAG2:p.T958S STAG2:p.L957F, SF3B1:p.L833F).

3. **Genomic subgroup 3**: AML with TP53 mutations, chromosomal aneuploidy, or both. We identified 37 patients in this subgroup, with a total of nineteen TP53 mutations, of which five were observed in more than one sample (TP53:p.S378P, TP53:p.T377P, TP53:p.A70G, TP53:p.T231P, TP53:p.R248Q).

![FIG 4](image-url) Visualization widgets that describe the variants analyzed in Case Study 2. (A) Protein Diagram displaying the 6 protein-coding KRAS variants. The Ras Pfam domain is indicated in tan along the Protein Diagram. (B) NDEx graphical widget showing the “Class I PI3K signaling events” network, where the mutation-harboring KRAS and PTEN are shown in red.
4. Genomic subgroup 4: AML with biallelic CEBPA mutations. No patients exhibited biallelic CEBPA mutations. However, 5 patients had a single mutation (CEBPA: p.V308dup, CEBPA:p.R300C, CEBPA:p.R343Af*79, CEBPA:p.R286Pfs*35, CEBPA:p.T310_Q311insKWNP).

5. Genomic subgroup 5: AML with IDH2 R172 mutations and no other class-defining lesions. We identified 4 patients in this subgroup with IDH2:p.R172K mutations. No other patients had a mutation that affected R172.

Of the 182 total patients in this cohort, 76 were assigned into the 5 molecular subgroups based on protein-coding somatic mutations. The remaining 50 patients most likely harbored inversions, translocations, and/or gene fusion events. We observed that 11 of the total 49 mutations occurred in more than 1 patient and may reflect recurrent driver mutations with prognostic value.

**DISCUSSION**

OpenCRAVAT is a flexible and dynamic system to annotate, evaluate, and visualize the characteristics of genetic variation. It has been designed to enable rapid characterization of variants, including functional impact, pharmacologic annotations, and both known and predicted relevance of genetic variants to disease, including cancer. The open store contains dozens of resources relevant to variant interpretation, with new additions weekly. Selection of specialized converters, annotators, and filtering criteria enable researchers to carry out complex analyses and integrate information from a wider array of resources than previously possible.

We have described a framework that includes both an advanced GUI for biologists and a command-line interface that supports advanced use cases, including development of custom bioinformatics pipelines. Both GUI and command line can be leveraged in the cloud to handle processing of genomes from large patient populations. Finally, because the OpenCRAVAT store is designed to be community driven, we have incorporated more than 100 tools from dozens of universities and institutes in the past year, and we are actively recruiting tool and resource developers.

**AFFILIATIONS**

1 The Institute for Computational Medicine, The Johns Hopkins University, Baltimore, MD  
2 In Silico Solutions, Falls Church, VA  
3 Mountain Genomics, Pittsburgh, PA  
4 Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD  
5 Dana-Farber Cancer Institute, Boston, MA  
6 Departments of Biomedical Engineering, Oncology, and Computer Science, The Johns Hopkins University, Baltimore, MD

**CORRESPONDING AUTHOR**

Rachel Karchin, MS, PhD, Johns Hopkins University, 3400 N Charles St, Baltimore, MD 21218; Twitter: @OpenCRAVAT; e-mail: karchin@jhu.edu.

**SUPPORT**

Supported by the National Cancer Institute, Grant No. U24 CA204817 (R.K.).

**AUTHOR CONTRIBUTIONS**

Conception and design: Kymberleigh A. Pagel, Ben Busby, Michael Ryan, Rachel Karchin  
Collection and assembly of data: Kymberleigh A. Pagel, Rick Kim, Kyle Moad, Rachel Karchin  
Data analysis and interpretation: Kymberleigh A. Pagel, Kyle Moad, Lily Zheng, Collin Tokheim, Rachel Karchin  
Manuscript writing: All authors  
Final approval of manuscript: All authors  
Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org/cc/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ben Busby  
Employment: DNAnexus, Ariel Precision Medicine  
Leadership: Ariel Precision Medicine  
Stock and Other Ownership Interests: DNAnexus  
Consulting or Advisory Role: Janssen, Deloitte  
Travel, Accommodations, Expenses: Cambridge Healthtech Institute

Michael Ryan  
Leadership: Kiromic  
Consulting or Advisory Role: Kiromic (Inst)

Rachel Karchin  
Patents, Royalties, Other Intellectual Property: I am an inventor on 1 technology that was licensed to Thrive Earlier Detection Corp, C15049. My contribution percentage to that technology is 3%. Accordingly, I am entitled to receive 3% of the inventors’ personal share of any distributions that are received by Johns Hopkins Technology Ventures from Thrive that are attributed to C15049

No other potential conflicts of interest were reported.
REFERENCES

1. OpenCRAVAT: Open Custom Ranked Analysis of Variants Toolkit. https://opencravat.org/index.html
2. Liu X, Jian X, Boerwinkle E: dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat 32:894-899, 2011
3. Reference deleted
4. Elbeek K, Quinlan A, Yandell M: Settling the score: Variant prioritization and Mendelian disease. Nat Rev Genet 18:599-612, 2017
5. Li MX, Gui HS, Kwan JS, et al: A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases. Nucleic Acids Res 40:e53, 2012
6. Santoni FA, Makrythanasis P, Nikolaev S, et al: Simultaneous identification and prioritization of variants in familial, de novo, and somatic genetic disorders with VariantMaster. Genome Res 24:349-355, 2014
7. Smedley D, Jacobsen JO, Jäger M, et al: Next-generation diagnostics and disease-gene discovery with the Exomiser. Nat Protoc 10:2004-2015, 2015
8. CRAVAT: Cancer-related Analysis of Variants Toolkit. https://cravat.us/CRAVAT/
9. Masica DL, Douville C, Tokheim C, et al: CRAVAT 4: Cancer-Related Analysis of Variants Toolkit. Cancer Res 77:a35-e38, 2017
10. Robinson JT, Thorvaldsdóttir H, Winckler W, et al: Integrative genomics viewer. Nat Biotechnol 29:24-26, 2011
11. Frankish A, Diekhans M, Ferreira AM, et al: GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res 47:D766-D773, 2019
12. Labidi-Galy SI, Papp E, Hallberg D, et al: High grade serious ovarian carcinomas originate in the fallopian tube. Nat Commun 8:1093, 2017
13. Cibulskis K, Lawrence MS, Carter SL, et al: Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31:213-219, 2013
14. Futreal PA, Coin L, Marshall M, et al: A census of human cancer genes. Nat Rev Cancer 4:177-183, 2004
15. Vogelstein B, Papadopoulos N, Velculescu VE, et al: Cancer genome landscapes. Science 339:1546-1558, 2013
16. Tokheim C, Karchin R: CHASMplus reveals the scope of somatic missense mutations driving human cancers. Cell Syst 9:9-23.e8, 2019
17. Li B, Krishnan VG, Mort ME, et al: Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics 25:2744-2750, 2009
18. Schaefer CF, Buchoff J, Krupa S, et al: PID: The Pathway Interaction Database. Nucleic Acids Res 37:D674-D679, 2009
19. Reiter JG, Makohon-Moore AP, Gerold JM, et al: Minimal functional driver gene heterogeneity among untreated metastases. Science 361:1033-1037, 2018
20. Mighell TL, Evans-Dutson S, O’Roak BJ: A saturation mutagenesis approach to understanding PTEN lipid phosphatase activity and genotype-phenotype relationships. Am J Hum Genet 102:943-955, 2018
21. OpenCRAVAT: Example analyses. https://opencravat.org/examples.html
22. Personal Genome Project: Public profiles—hu3BDC4B. https://my.pgp-hms.org/profile/hu3BDC4B
23. Church GM: The personal genome project. Mol Syst Biol 1:2005.0030, 2005
24. Landrum ML, Lee JM, Riley GR, et al: ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42:D980-D985, 2014
25. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414-417, 2012
26. Strande NT, Riggs ER, Buchanan AH, et al: Evaluating the clinical validity of gene-disease associations: An evidence-based framework developed by the clinical genome resource. Am J Hum Genet 100:895-906, 2017
27. Papaemmanuil E, Gerstung M, Bullinger L, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209-2221, 2016
28. Ahn JS, Kim HJ, Kim YK, et al: Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. Oncotarget 9:4961-4968, 2017
29. El-Gebali S, Mistry J, Bateman A, et al: The Pfam protein families database in 2019. Nucleic Acids Res 47:D427-D432, 2019